Microbix and Zydus Cadila have announced that they have signed a Letter of Intent to market the Thrombolytic drug, Urokinase, in the North American markets.
Microbix’ LumiSort™ semen sexing technology is the result of research focused on the question of delivering high quality sexed semen to the livestock industry.
Microbix holds a valuable portfolio of intellectual property in virology, large market biotherapeutic drugs, vaccine technologies, and animal reproduction technologies.
VIRUSMAX™ technology is a process for recovery of more virus from influenza virus-infected chick embryos (eggs) to enhance influenza vaccine production.
